Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Interpretable Dynamic Directed Graph Convolutional Network for Multi-Relational Prediction of Missense Mutation and Drug Response

DualGCN: a dual graph convolutional network model to predict cancer drug response

Interpretable Drug Response Prediction through Molecule Structure-aware and Knowledge-Guided Visible Neural Network

Controllable Edge-Type-Specific Interpretation in Multi-Relational Graph Neural Networks for Drug Response Prediction

Predicting cancer drug response using parallel heterogeneous graph convolutional networks with neighborhood interactions

HMM-GDAN: Hybrid Multi-View and Multi-Scale Graph Duplex-Attention Networks for Drug Response Prediction in Cancer.

DRExplainer: Quantifiable Interpretability in Drug Response Prediction with Directed Graph Convolutional Network

XGraphCDS: An explainable deep learning model for predicting drug sensitivity from gene pathways and chemical structures

Improving anti-cancer drug response prediction using multi-task learning on graph convolutional networks

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

DRPreter: Interpretable Anticancer Drug Response Prediction Using Knowledge-Guided Graph Neural Networks and Transformer

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

SMGCN: Multiple Similarity and Multiple Kernel Fusion Based Graph Convolutional Neural Network for Drug-Target Interactions Prediction.

drGAT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network

DGCddG: Deep Graph Convolution for Predicting Protein-Protein Binding Affinity Changes Upon Mutations

Predicting Drug Response Based on Multi-Omics Fusion and Graph Convolution

TG468: A Text Graph Convolutional Network for Predicting Clinical Response to Immune Checkpoint Inhibitor Therapy

Interpretable Drug Synergy Prediction with Graph Neural Networks for Human-AI Collaboration in Healthcare

GCNGAT: Drug–disease association prediction based on graph convolution neural network and graph attention network

XMR: an explainable multimodal neural network for drug response prediction

SWnet: a deep learning model for drug response prediction from cancer genomic signatures and compound chemical structures